Lexicon Pharmaceuticals, Inc. (LXRX) key performance indicators and operating metrics (5 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Sotagliflozin SONATA Hypertrophic Cardiomyopathy Targeted Enrollment | 500.00 | FY2026-Q1 |
| INPEFA (Sotagliflozin) Net Sales | 1.1M | FY2025-Q4 |
| Licensing Revenue from Novo Nordisk Agreement | 4.3M | FY2025-Q4 |
| SONATA Hypertrophic Cardiomyopathy Sites Initiated | 130.00 | FY2025-Q4 |
| SONATA Hypertrophic Cardiomyopathy Countries with Sites Initiated | 20.00 | FY2025-Q3 |
Back to LXRX overview · LXRX earnings · LXRX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.